Quarterly ResultMay 4, 2026, 04:13 PM
Vertex Q1 Revenue +8% to $2.99B; Povetacicept BLA Submitted
AI Summary
Vertex Pharmaceuticals reported strong first-quarter 2026 financial results, with total revenue increasing 8% to $2.99 billion and GAAP net income rising to $1.0 billion. The company reiterated its full-year 2026 financial guidance. Key pipeline advancements include the completion of a rolling BLA submission for povetacicept in IgA nephropathy and the U.S. regulatory submission for CASGEVY in children aged 5 to less than 12 years old. Vertex also saw continued growth in its CF therapies and new product launches like CASGEVY and JOURNAVX.
Key Highlights
- Total revenue increased 8% to $2.99 billion in Q1 2026.
- GAAP net income was $1.0 billion, up from $646 million in Q1 2025.
- Non-GAAP net income rose to $1.1 billion, an increase of $93 million YoY.
- Cash, cash equivalents, and marketable securities totaled $13.0 billion as of March 31, 2026.
- Reiterated full-year 2026 total revenue guidance of $12.95 billion to $13.1 billion.
- Completed rolling BLA submission for povetacicept in IgA nephropathy for accelerated approval.
- Completed U.S. regulatory submission for CASGEVY in children ages 5 to less than 12 years.
- CASGEVY generated $43 million and JOURNAVX $29 million in Q1 2026 revenue.